Key result
Empagliflozin significantly improved exercise tolerance, decreased left ventricular filling pressure, and restored diastolic and chronotropic reserves compared to standard hypoglycemic therapy.
Why the study?
The study evaluated the effect of empagliflozin on exercise tolerance and left ventricular diastolic function in patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus.
Does empagliflozin improve exercise tolerance and left ventricular diastolic function in patients with HFpEF and T2DM?
RCT (n=80)
Open-label
1:1
Does empagliflozin improve exercise tolerance and left ventricular diastolic function in patients with HFpEF and T2DM?
Empagliflozin improves exercise capacity and echocardiographic markers of diastolic function in patients with HFpEF and T2DM.
Answers are grounded in this paper and cite their sources.
Empagliflozin may enhance functional status in diabetic HFpEF; extends SGLT2i outcome data to exercise and diastolic endpoints.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Овчинников et al. (2021) conducted an RCT in Heart failure with preserved ejection fraction and type 2 diabetes mellitus (n=80). Empagliflozin vs. Standard hypoglycemic therapy was evaluated on Exercise tolerance and left ventricular diastolic function. Empagliflozin significantly improved exercise tolerance, decreased left ventricular filling pressure, and restored diastolic and chronotropic reserves compared to standard hypoglycemic therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: